ProteinQure Strengthens Leadership Team with Strategic Appointments

ProteinQure, a leader in computational peptide design, has announced two key additions to its leadership team. Dr. Dave Garman assumes the role of Vice President of Translation and Development while Dr. Edward Garmey joins as consulting Chief Medical Officer. These appointments aim to bolster ProteinQure's push in advancing its clinical program assets, notably PQ203.

PQ203 is an innovative peptide-drug conjugate targeting hormone receptor "triple" negative breast cancer. Dr. Garman will be leading efforts in translational research, focusing on operations, manufacturing, and regulatory strategies. Dr. Garmey brings two decades of oncology expertise to guide the clinical strategy for PQ203's development.

These strategic hires mark a pivotal phase for ProteinQure as it continues to expand its influence in computational drug discovery, targeting complex diseases with novel therapeutics.